Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10353479 | 0.98 | LOXL2 (0.60) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| Hydrochloric Acid SCHEMBL17260639 | 0.98 | LOXL2 (0.60) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL15807619 | 0.98 | LOXL2 (0.60) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL43299 | 0.94 | LOXL2 (0.64) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| Hydrochloric Acid SCHEMBL7504059 | 0.92 | LOXL2 (0.62) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL18913824 | 0.90 | TSHR (0.69) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL335044 | 0.86 | LOXL2 (0.69) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL30758863 | 0.86 | TSHR (0.69) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL447386 | 0.85 | TSHR (0.58) | LOXL2TSHRKCNJ1KCNH2IDO1 | |
| SCHEMBL16572121 | 0.84 | KCNH2 (0.57) | LOXL2TSHRKCNJ1KCNH2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | claimed |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | VERSITECH LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-01-26 | — | — | US | disclosed |
| EP-4065590-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | Aurigene Discovery Technologies Limited (IN) | 2022-10-05 | — | — | EP | disclosed |
| CN-114728998-A | Sulfonamide compounds targeting CD73 and adenosine receptors | 奥瑞基尼探索技术有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-110950781-A | Novel diamine, polyamic acid, and polyimide | 日产化学工业株式会社 | 2020-04-03 | — | — | CN | disclosed |
| CN-106883224-B | 1 inhibitor of nitrogen-containing benzoheterocycle class indoles amine -2,3- dioxygenase and application thereof | 中国药科大学 | 2019-10-22 | — | — | CN | disclosed |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004051221-A2 | MEASUREMENT OF TOTAL REACTIVE ISOCYANATE GROUPS IN SAMPLES USING BIFUNCTIONAL NUCLEOPHILES SUCH AS 1,8-DIAMINONAPHTHALENE (DAN) | THE GOVERNMENT OF THE UNITED STATES OF AMERICA (US) | 2004-06-17 | — | — | WO | disclosed |
| US-6656737-B1 | Reacting 9-anthracenemethanol, pyridine, and p-nitrophenyl chloroformate; reacting the product with an amine, especially piperazine, to form a product that can be used to determine the total amount of isocyanate in a sample | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-02 | — | — | US | disclosed |
| US-6290923-B1 | CONTAMINANT-CONTAINING AIR IS TAKEN UP FROM THE IMMEDIATE ENVIRONMENT OF A POLYURETHANE FOAM PROCESSING LINE COMPRISING PASSING THE ORGANIC CONTAMINANT-CONTAINING AIR THROUGH A PACKED TOWER SCRUBBER MATERIAL | WM. T. BURNETT & CO. | 2001-09-18 | — | — | US | disclosed |
| EP-1077962-A2 | ISOCYANATE DERIVATIZING AGENT AND METHODS OF PRODUCTION AND USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058517-A2 | ISOCYANATE DERIVATIZING AGENT AND METHODS OF PRODUCTION AND USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
| US-4336269-A | ANTIARRHYTHMIA | ELI LILLY AND COMPANY (US) | 1982-06-22 | — | — | US | disclosed |
| US-4277501-A | ANTIARRHYTHMIA AGENTS | ELI LILLY AND COMPANY (US) | 1981-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | H1-2, H1-4, H1-0 | LOXL2 1404/4885TSHR 2393/4885KCNJ1 4460/4885 |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | LOXL2 3586/4885TSHR 1950/4885KCNJ1 28/4885 |
| US-20230121302-A1 | METHODS OF IRON CATALYZED C-H BOND AMINATION | FTH1, FECH, HCCS | LOXL2 3663/4885TSHR 1353/4885KCNJ1 1210/4885 |
| US-20230027075-A1 | SULFONAMIDE COMPOUNDS TARGETING CD73 AND ADENOSINE RECEPTORS | ADORA2A, ADORA2B, ENTPD5 | LOXL2 3751/4885TSHR 134/4885KCNJ1 1515/4885 |
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | LOXL2 3970/4885TSHR 480/4885KCNJ1 1912/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | LOXL2 4490/4885TSHR 762/4885KCNJ1 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.